Key points from article :
AKL Therapeutics’ investigational oral osteoarthritis drug APPA may have a dual effect on senescence with potential in other diseases of aging.
Senescence plays a major role in the development of many age-related diseases, including osteoarthritis.
It found that APPA appears to
- reduce the number of harmful senescent cells which build up in the cartilage causing inflammation – a senolytic effect
- but could also potentially reverse the senescence process so cells can function normally again – a senomorphic effect.\
Alan Reynolds, Chief Scientific Officer, says: “These latest findings raise the tantalising possibility that APPA ... cellular senescence and the process of ageing.”
Developing a new class of drugs called senotherapeutics to eliminate or delay the damaging effects of this cellular senescence.
APPA is an oral, patented, fixed-dose combination of two synthetically produced, synergistic, secondary metabolites of plant origin.